| abstract |
The present invention relates to pharmaceutical compositions containing S-methyl-dihydro-ziprasidone and to the use of such compounds and pharmaceutically acceptable salts thereof for the treatment of psychiatric disorders and eye diseases. More specifically, anxiety disorders such as schizophrenia, generalized anxiety disorder, panic disorder, post-traumatic stress disorder and phobia (eg, interpersonal phobia, agoraphobia, etc.); Psychotic episodes of anxiety: social or emotional regression associated with anxiety, nervousness, excessive aggressiveness, tension or psychosis; Psychotic emotional disorders, such as severe depressive disorders; Emotional disorders associated with psychotic disorders such as acute mood swings associated with bipolar disorder, emotional disorders associated with schizophrenia; Behavioral disorders associated with mental retardation, autism disorder, and behavioral disorders; Dementia, such as dementia associated with Alzheimer's disease; Drug-induced dyskinesia and dyskinesias of neurodegenerative origin; Obsessive compulsive disorder; Tourette's syndrome; glaucoma; And S-methyl-dihydro-ziprasidone or a pharmaceutically acceptable salt thereof for treating a disorder or condition selected from ischemic retinopathy. |